Benzinga | Nov 4, 2021 09:38AM EDT

TG Therapeutics Highlights Data Selected For Presentation At The 63rd American Society Of Hematology Annual Meeting

TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the release of six abstracts that will be presented at the upcoming 63rd American Society of Hematology (ASH) annual meeting and exposition, to be held December 11 -- 14, 2021, virtually and also live at the Georgia World Congress Center in Atlanta, Georgia. Abstracts are now publicly available online via the ASH meeting website at www.hematology.org.

Michael S. Weiss, Chairman and Chief Executive Officer, stated, "We are looking forward to a live ASH annual meeting this year where we will be sharing six presentations, including three oral presentations. Specifically, we are pleased to share new data from the UNITY-NHL Phase 2b trial showing the U2 combination in patients with relapsed or refractory marginal zone lymphoma and diffuse large b-cell lymphoma. We are also excited to share two novel analyses from the UNITY-CLL Phase 3 trial. One highlighting the outcomes of U2 treated patients who had comorbidities or required certain concomitant medications, both of which represent areas of high unmet need as these patients may be poor candidates for BTK therapy. The other presentation sharing the efficacy and safety of U2 by CLL pre-treatment status, that is, comparing the treatment na?ve cohort with the previously treated cohort. Finally, we will also share two presentations from studies evaluating U2 triplet regimens with a BTK, namely TG-1701 and ibrutinib. We believe these presentations showcase the strength of our combination B-cell platform, which has the potential to produce multiple product opportunities in the future."